


Robert F. Ozols

Symposium on

GYN Cancer



GYN CANCERS – THE NEXT 25 YEARS

FRIDAY, SEPTEMBER 25, 2009

Sponsored by

**FOX CHASE
CANCER CENTER**

Philadelphia, PA

LOCATION

Fox Chase Cancer Center • 333 Cottman Avenue • Philadelphia, PA 19111

At the time of publication, the following companies have provided educational grants to support this activity: **Bristol-Myers Squibb, Centocor Ortho Biotech Services LLC, Eisai, Genentech and sanofi-aventis U.S. Inc.**

STATEMENT OF NEED

Evolving medical, surgical, diagnostic and molecular advances continue to expand our ability to treat gynecologic cancers in a more effective manner and improve patient outcomes. New chemotherapeutic and biological therapies are emerging and molecular criteria and diagnostic tests are available to select patients who may respond to new therapies and identify patients who can be spared unnecessary toxicities from treatments which are unlikely to be beneficial. Combined modality procedures and neoadjuvant therapies are being studied in women with certain gynecologic cancers.

This conference is designed as a forum for discussion of advances in gynecologic cancers that will help oncologists, gynecologists and advanced practice clinicians to evaluate and recommend appropriate strategies for managing patients with ovarian, endometrial and cervical cancers and enhance the physician's ability to counsel patients about available treatments. There will be ample time for participants to ask questions and interact with the speakers. Participants are encouraged to submit interesting cases for discussion.

OBJECTIVES

Following this activity, participants should be able to:

1. Assess advanced ovarian cancer patients to determine who should be candidates for neoadjuvant chemotherapy.
2. Compare the data from different clinical trials to assess the role of maintenance chemotherapy in patients with advanced ovarian cancer.
3. Evaluate the role of DNA repair inhibition in patients with BRCA 1/2 ovarian cancer.
4. Apply diagnostic criteria for select patients with early stage ovarian cancer who may benefit from adjuvant chemotherapy.
5. Assess patients with early stage endometrial cancer to determine the role and type of postoperative radiation.
6. Assess patients with advanced endometrial cancer to determine the use of chemotherapy or radiation.
7. Analyze the criteria for determining which patients with locally advanced cervical cancer benefit from combined modality therapy.

TARGET AUDIENCE

This program is designed for gynecologists, medical, surgical and radiation oncologists. Other physician specialties and advanced practice clinicians who manage patients with gynecologic cancers may find the program beneficial.

ACCREDITATION STATEMENT

The Fox Chase Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Fox Chase Cancer Center designates this educational activity for a maximum of 7 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

INQUIRIES

For additional information, please contact the Office of Continuing Medical Education, Fox Chase Cancer Center, Telephone: **215-728-5358**; Fax: **215-214-8908**;
E-mail: **kathy.smith@fcc.edu**

REGISTRATION

REGISTRATION IS REQUIRED! Deadline: September 21, 2009

The conference is offered at no charge. Complete the Registration Form and return to **Fox Chase Cancer Center**, Attn: Kathy Smith, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111; Fax to **215-214-8908** or Email **kathy.smith@fcc.edu**.

INTERESTING CASES

If you have an interesting case that you would like us to consider for discussion, please send a description of the case by **September 15, 2009** to the Office of CME, Fax: **215-214-8908**;
Email: **kathy.smith@fcc.edu**.

DIRECTIONS/PARKING

Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.
Directions are available at www.fcc.edu.

ACCOMMODATIONS

Hyatt Regency Philadelphia, 201 South Columbus Boulevard, Philadelphia, PA 19106

Make your hotel reservations directly by calling the Hyatt Regency Philadelphia Reservation Department at **215-928-1234** or **1-800-233-1234**.

Group Name: FOX CHASE SPORE (*Group name required to get room block*).

Rates:	Single or Double Occupancy	\$159
	Triple Occupancy	\$184
	Quadruple Occupancy	\$209

(Rates do not include 15.2% state and local taxes per room per night. Rates guaranteed until room block filled or cut-off date)

CUT-OFF DATE: September 3, 2009

PROGRAM

7:30 am **Registration and Continental Breakfast**

SESSION I: OVARIAN CANCER

8:00 am **Welcome**
Robert C. Young, M.D.

8:15 am **Ovarian Cancer Chemotherapy Past, Present and Future**
Dr. Peter George Harper, F.R.C.P., M.R.C.S.

8:45 am **The Promise of Immune Therapy in Ovarian Cancer**
George Coukos, M.D., Ph.D.

9:15 am **The Future of Anti-Cancer Drugs: Determining Value, Looking at Science, Struggling with Costs**
Sergio L. Pecorelli, M.D., Ph.D.

9:45 am **Genetic Analysis of the Early Natural History of Ovarian Cancer**
Jeff Boyd, Ph.D.

10:15 am **BREAK**

10:30 am **Epithelial Ovarian Cancer: A Real Challenge for the Future**
Prof. Claes G. Tropé, M.D., Ph.D.

11:00 am **Future of Ovarian Cancer Screening and Biomarkers**
Nicole Urban, M.S., Sc.D.

11:30 am **Ovarian Panel Discussion** – Chair, Michael A. Bookman, M.D.
• Robert C. Bast Jr., M.D.
• Charles W. Drescher, M.D.
• Lynn C. Hartmann, M.D.
• Dr. Lalit Kumar, M.D., D.M., F.A.M.S.
• Mark A. Morgan, M.D., F.A.C.O.G., F.A.C.S.

12:30 pm **LUNCH**

PROGRAM

SESSION II: GYN MALIGNANCIES

1:15 pm **Welcome**
Thomas C. Hamilton, Ph.D.

1:30 pm **Improving Outcomes in Cervical Cancer: Clinical Trials, A Conundrum**
Gillian Thomas, M.D., F.R.C.P.C.

2:00 pm **Surgical Therapies for Gynecologic Malignancies: The Next 25 Years**
William J. Hoskins, M.D.

2:30 pm **Individualized Treatment in Endometrial Cancer;
Do We Make Progress?**
Prof. Dr. Jan G. Aalders, M.D., Ph.D.

3:00 pm **BREAK**

3:15 pm **Provocative Recommendations for the Future of
Gynecologic Cancer Research**
Michael V. Seiden, M.D., Ph.D.

3:45 pm **Patient Perspective**
April Donahue

3:50 pm **GYN Panel Discussion** – Chair, Stephen C. Rubin, M.D.
• Jonathan S. Berek, M.D., M.M.S.
• Paul Goodfellow, Ph.D.
• Karen H. Lu, M.D.
• Maurie Markman, M.D.

4:50 pm **Closing Remarks**
Robert C. Young, M.D.

5:00-6:00 pm **NETWORKING RECEPTION**
Opportunity for informal discussion with speakers and colleagues.

FACULTY

Prof. Dr. Jan G. Aalders, M.D., Ph.D.

Abeltoft, Denmark

Robert C. Bast Jr., M.D.

Harry Carothers Wiess Distinguished
University Chair for Cancer Research
Vice President for Translational Research
Professor of Medicine,
Dept. of Experimental Therapeutics,
Div. of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX

Jonathan S. Berek, M.D., M.M.S.

Professor and Chair, Dept. of OB/GYN
Stanford University School of Medicine
Co-Director, Women's Cancer Program
Div. of Gynecologic Oncology
Stanford Cancer Center
Stanford, CA

Michael A. Bookman, M.D.

Professor of Medicine
Chief, Hematology-Oncology
Arizona Cancer Center
Tucson, AZ

Jeff Boyd, Ph.D.

Senior Vice President
Chief Scientific Officer
Robert C. Young Chair in Cancer Research
Fox Chase Cancer Center
Philadelphia, PA

George Coukos, M.D., Ph.D.

Celso Ramon Garcia Chair
in Reproductive Biology
Director, Ovarian Cancer Research Center
Associate Chief, Division of Gynecologic Oncology,
Div. Gynecology/Oncology
University of Pennsylvania
Philadelphia, PA

April Donahue

Patient Advocate
President, National Ovarian Cancer Coalition

Charles W. Drescher, M.D.

Pacific Gynecologic Specialists
Clinical Professor
University of Washington
Seattle, WA

Paul Goodfellow, Ph.D.

Professor of Surgery, Genetics, Obstetrics
and Gynecology
Washington University School of Medicine
Endometrial Cancer SPORE Director
Siteman Cancer Center/ Barnes-Jewish Hospital
St. Louis, MO

Thomas C. Hamilton, Ph.D.

Professor Women's Cancer Center
Fox Chase Cancer Center
Philadelphia, PA

FACULTY

**Dr. Peter George Harper, F.R.C.P.,
M.R.C.S.**

Consultant to Guy's and St. Thomas Hospital
Founding Partner, The London Oncology Clinic
Chairman, Toulouse Cancer Center
London, United Kingdom

Lynn C. Hartmann, M.D.

Blanche R. and Richard J. Erlanger
Professor of Medical Research
Professor of Oncology
Mayo Clinic
Rochester, MN

William J. Hoskins, M.D.

Executive Director of Surgical Activities
Attending Surgeon, Gynecology Service
Dept. of Surgery and Member
Memorial Sloan-Kettering Cancer Center
New York, NY

Dr. Lalit Kumar, M.D., D.M., F.A.M.S.

Professor of Medical Oncology
Institute Rotary Cancer Hospital (IRCH)
All India Institute of Medical Sciences
New Delhi, India

Karen H. Lu, M.D.

Professor of Gynecologic Oncology
Director, Uterine SPORE
Dept. of Gynecologic Oncology
MD Anderson Cancer Center
Houston, TX

Maurie Markman, M.D.

Vice President for Clinical Research
Chairman, Dept. of Gynecologic
Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX

**Mark A. Morgan, M.D.,
F.A.C.O.G., F.A.C.S.**

Chief of Gynecologic Oncology
Fox Chase Cancer Center
Philadelphia, PA

Sergio L. Pecorelli, M.D., Ph.D.

Editor European Institute of Oncology
Milan, Italy

Stephen C. Rubin, M.D.

Franklin Payne Professor
Chief, Div. of Gynecologic Oncology
University of Pennsylvania Health System
Philadelphia, PA

Michael V. Seiden, M.D., Ph.D.

President and CEO
Fox Chase Cancer Center
Philadelphia, PA

Gillian Thomas, M.D., F.R.C.P.C.

Professor, Department of Radiation Oncology,
University of Toronto
Sunnybrook Odette Cancer Centre
Toronto, ON, Canada

continued on next page

FACULTY (cont.)

Prof. Claes G. Tropé, M.D., Ph.D.

Professor and Head of R & D
The Norwegian Radium Hospital
Oslo University Hospital
Dept. of Gynaecological Oncology
Oslo, Norway

Nicole Urban, M.S., Sc.D.

Co-Program Head, Women's Cancer
Research Program
Molecular Diagnostics Program
Fred Hutchinson Cancer Research Center
Seattle, WA

Robert C. Young, M.D.

Fox Chase Cancer Center
Philadelphia, PA

FOX CHASE CANCER CENTER DISCLOSURE POLICY

It is the policy of Fox Chase Cancer Center to ensure that all sponsored continuing medical education activities are independently designed and produced and include valid content that is objective, balanced, free of commercial bias and in the best interest of the public. Fox Chase Cancer Center policy requires everyone in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest pertaining to the content of the activity. Individuals who refuse to disclose cannot have control of or responsibility for activity content. Conflicts of interest will be resolved prior to the activity. Fox Chase Cancer Center requires disclosure to the activity audience of relevant financial relationships of those with control over CME content and support from commercial interests.

REGISTRATION FORM

Robert F. Ozols Symposium on GYN Cancer,
GYN CANCERS – THE NEXT 25 YEARS

Name _____

(Please print/type name and degree as you would like them to appear on your nametag/certificate.)

Degree _____

Medical Specialty _____

Institution/Affiliation _____

Preferred Mailing Address _____

City _____

State _____ Zip _____

Daytime Phone _____ Fax _____

E-mail _____

Check if you are a: Fellow Resident Medical School _____

Indicate Fox Chase Partner Affiliation _____

Specify questions/issues you would like speakers to address. _____

REGISTRATION IS REQUIRED! Deadline: September 21, 2009

The conference is offered at no charge. Complete the Registration Form and return to **Fox Chase Cancer Center**, Attn: Kathy Smith, Office of CME, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111.

Fax to **215-214-8908** or Email **kathy.smith@fcc.edu**.

SPECIAL NEEDS

ADA: If you require auxiliary aids or services as identified in the Americans with Disabilities Act, please specify: _____

Dietary: Kosher Vegetarian Other (Specify)



FOX CHASE CANCER CENTER

Philadelphia, PA • www.fccc.edu

Telephone: 215-728-5358 • Fax: 215-214-8908